Is Panitumumab a targeted drug?

Panitumumab (Panitumumab) is a targeted drug. It belongs to the monoclonal antibody category of anti-cancer biologics and works by specifically binding to and inhibiting the epidermal growth factor receptor (EGFR) on tumor cells. It is mainly used in the treatment of patients with KRAS mutation-negative metastatic colorectal cancer, as well as other tumor types determined to overexpress EGFR. But not all patients respond equally well to panitumumab or other targeted drugs.

EGFR is a membrane receptor that participates in the signaling process of cell growth, differentiation and survival. In some malignant tumors, EGFR is overexpressed or mutated, leading to abnormal signaling and promoting tumor growth and spread. Panitumumab inhibits the growth and proliferation of tumor cells by binding to EGFR and preventing its activation and downstream signaling. Targeted drugs have a more precise mechanism of action, are more selective in causing damage to tumor cells than traditional chemotherapy drugs, and usually have lower toxic and side effects. If patients require treatment with panitumumab, they will need to be tested for the presence of wild-type RAS.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.